Try it
OBG · Gynaecological oncology: tamoxifen
Sample itemA woman on long-term tamoxifen for breast cancer develops postmenopausal bleeding. Which gynaecological risk is increased by tamoxifen?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
B. Endometrial polyps and carcinoma
Tamoxifen acts as an oestrogen agonist on the endometrium, causing hyperplasia, polyps and a 2 to 3-fold rise in endometrial carcinoma. Any bleeding needs evaluation. Routine screening of asymptomatic women is not recommended.
Option by option
A. Vulval cancer
Vulval cancer is not increased.
B. Endometrial polyps and carcinoma (correct)
Correct. Tamoxifen stimulates the endometrium.
C. Ovarian cancer
Ovarian cancer is not increased.
D. Cervical cancer
Cervical cancer is not increased.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More OBG questions
- Antenatal careA woman's last menstrual period began on 10 January 2026. Using Naegele's rule, what is…
- Obstetric drugsCarboprost (15-methyl PGF2α) is contraindicated in which condition?
- Hypertensive disorders of pregnancyA primigravida at 34 weeks has a blood pressure of 150/100 mmHg on two occasions and 2+…
- Obstetric immunologyAn Rh-negative mother delivers an Rh-positive baby. When should anti-D immunoglobulin be…